Further to this, the ratio of CD4+CD25+FOXP3+ Tregs to effector CD8+ T cells in the tumor can be an important predictor of mortality in ovarian cancer, with higher amounts of Tregs compared to the effector CD8+ T cells being correlated with poorer clinical outcomes and reduced long-term survival [8]. This evidence concerns the gene CD8A and neoplasm.